about
Tomatoes, lysophosphatidic acid, and the small intestine: new pieces in the puzzle of apolipoprotein mimetic peptides?Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a reviewIn vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I.Apolipoprotein A-I mimetics.An apolipoprotein A-I mimetic peptide designed with a reductionist approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice.Source and role of intestinally derived lysophosphatidic acid in dyslipidemia and atherosclerosis.Small lipidated anti-obesity compounds derived from neuromedin U.Efficacy of tomato concentrates in mouse models of dyslipidemia and cancer.ApoA-I mimetics: tomatoes to the rescueTg6F ameliorates the increase in oxidized phospholipids in the jejunum of mice fed unsaturated LysoPC or WD.HDL, Atherosclerosis, and Emerging TherapiesTransintestinal transport of the anti-inflammatory drug 4F and the modulation of transintestinal cholesterol effluxTransgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acidCurrent guidelines for high-density lipoprotein cholesterol in therapy and future directions.Role of HDL in those with diabetes.High-density lipoprotein-based drug discovery for treatment of atherosclerosis.High Density Lipoprotein Cholesterol Increasing Therapy: The Unmet Cardiovascular Need.High-density lipoprotein mimetics: promises and challenges.The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease.Intestinal phospholipid and lysophospholipid metabolism in cardiometabolic disease.The potential of apolipoprotein mimetic peptides in the treatment of atherosclerosisAntioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit.Transgenic tomatoes expressing the 6F peptide and ezetimibe prevent diet-induced increases of IFN-β and cholesterol 25-hydroxylase in jejunum.Mimetic peptides of human apoA-I helix 10 get together to lower lipids and ameliorate atherosclerosis: is the action in the gut?Apolipoprotein A-1 mimetic peptide 4F promotes endothelial repairing and compromises reendothelialization impaired by oxidized HDL through SR-B1.Treating the Intestine with Oral ApoA-I Mimetic Tg6F Reduces Tumor Burden in Mouse Models of Metastatic Lung Cancer.HDL Mimetics Infusion and Regression of Atherosclerosis: Is It Still Considered a Valid Therapeutic Option?
P2860
Q33356762-E400C9C9-DC45-4A07-9DB9-F03DF02DA760Q34238630-CE2654D6-E20F-4EFC-9577-B3E42D056A84Q34238652-A76743D5-3535-4012-B413-56C681A45BADQ34421191-7205CCE9-504F-488F-9711-DB4C1329A7AFQ34851167-7513104E-51C1-4F12-B0B9-12DF22CE2CBDQ35217048-F5F1FBF0-EBFF-4DD0-988F-2AA1CA4917DCQ35708420-3F574D9F-4825-4235-90C5-5B803D9AD239Q35822272-51F9E1FC-18CB-427E-B981-6C468CA322F5Q36709622-7F0306D2-94C9-4878-9554-188EA2065D81Q36843312-860C1904-17BD-4856-9D93-284891F9C073Q36918309-1DC4598C-5213-49C4-883D-7CB67769AFD6Q37033119-E0148937-BDC1-4EE0-BC34-D5DF5BF3D2B4Q37305392-22AFDBEF-84C4-48CB-A89B-6F830E7CE719Q37702199-458DF0B2-7033-4233-A0CF-8F5DF4AB170AQ38221965-99E97E79-2AD8-45EC-88D4-9865276336F8Q38506490-72479F2C-1B42-49DD-AAE5-4B41775906EBQ38624772-70CD1CFA-78AD-4079-9B27-AC0CA6CE7D01Q38650575-368590D6-2FF1-42EC-8260-108ADDBC00A3Q38767234-D4DA3D83-E1FB-41C8-B1BF-A04779FC0D76Q38903367-02D162ED-3127-4A4E-83C2-6A5EF952C2A4Q40492051-F8089F32-3B7D-4357-AD50-145B49A6526AQ41115717-3B4F55CF-E865-493F-8AAE-CC36D0631A00Q42879444-A8D16AEF-A116-4683-A24D-1E3859B357B9Q42913663-AA3B661D-B573-41A3-9CF2-E74FFD94670EQ49582789-25AEC27A-8951-423A-96B6-74B7CE245BCEQ55222132-84C575AD-D012-4033-A4EA-2825CC3936C1Q55257404-A5200EA8-F93A-4E9E-ADEC-A45A8CBAC621
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A novel approach to oral apoA-I mimetic therapy
@ast
A novel approach to oral apoA-I mimetic therapy
@en
type
label
A novel approach to oral apoA-I mimetic therapy
@ast
A novel approach to oral apoA-I mimetic therapy
@en
prefLabel
A novel approach to oral apoA-I mimetic therapy
@ast
A novel approach to oral apoA-I mimetic therapy
@en
P2093
P2860
P356
P1476
A novel approach to oral apoA-I mimetic therapy
@en
P2093
Alan C Wagner
Alan M Fogelman
Arnab Chattopadhyay
Brian J Van Lenten
David Meriwether
G M Anantharamaiah
Greg Hough
James R Springstead
P2860
P304
P356
10.1194/JLR.M033555
P577
2013-02-02T00:00:00Z